Tournay Biotechnologies, a family owned company founded in 1992, produces extracts including cranberry, green coffee and green tea. The company, recognized for its unique know-how in the extraction of botanical ingredients and technological innovation, has an ISO 22000 certified and state-of-the-art manufacturing facility located near Bordeaux, France.
Tournay Biotechnologies has an extensive product portfolio, including its flagship brand Exocyan, a product line of cranberry extracts standardized on proanthocyanidines (PACs) content. PACs are condensed tannins, a type of flavonoid, with antioxidant and other health activities.
With this new acquisition Nexira, one of the world’s leaders in natural ingredients, is expanding its range of ingredients and reinforcing its positioning toward the health and wellness market, which will soon represent 35% of its commercial activity. Nexira confirms its growth target of 125 million euros in consolidated sales by 2015.
“We are pleased to welcome the Tournay Biotechnologies personnel, with whom we share family values. We are confident that this acquisition is aligned with the expansion plan that we announced one year ago” said Stéphane Dondain, president of Nexira.
“The acquisition of Tournay Biotechnologies by Nexira will give to the company an international dimension, essential to accelerate its expansion” added Cédric Tournay, president of Tournay Biotechnologies
Terms of the transaction, which will be finalized at the end of October, were not disclosed.
